Introduction: This ongoing, prospective,
pathway, on the basis of comparable quality, safety, and efficacy to the reference product (Genotropin Ò , Pfizer) [1] . Omnitrope is licensed for use to treat growth disturbances in the following pediatric indications: growth hormone deficiency (GHD), Turner syndrome, chronic renal insufficiency, Prader-Willi syndrome, and short children born small for gestational age (SGA) [2] .
Depending on the definition used, up to 10% of all live births each year are described as SGA [3] . Most children born SGA achieve appropriate catch-up growth by the age of 2-3 years, although approximately 10% do not; these children are at heightened risk of short stature in adulthood [3, 4] . In addition to short stature, SGA infants may be predisposed to altered body composition and (in adult life) hypertension and cardiovascular disease [4] [5] [6] [7] . Data from epidemiological studies indicate that children born SGA are also at increased risk of insulin resistance and type 2 diabetes in adulthood [8, 9] . rhGH therapy has been shown to induce transient resistance to the actions of insulin in children; therefore, concerns exist over the diabetogenic potential of rhGH therapy in children born SGA.
There are only limited data on the long-term use of rhGH in SGA children and the impact of treatment on diabetes in this population. This ongoing, long-term, phase IV, multicenter study with Omnitrope is the largest prospective clinical study so far conducted of rhGH in SGA patients [10] . In this paper, data are reported for patients who have completed 2 years of treatment.
METHODS

Study Design and Patients
The study design has been reported in detail previously [10] 
Study Objectives
The primary study objective is to assess the long-term effect of Omnitrope treatment on the development of diabetes in short children born SGA. Secondary objectives include evaluation of efficacy through changes in height parameters, incidence and severity of adverse events (AEs), occurrence of malignancies during treatment, and detection of anti-rhGH antibodies during treatment. 
Timing of Study Assessments
Height is measured in cm and HV calculated.
HSDS and HVSDS (based on the relevant
country-specific reference tables) are assessed at baseline and at 3-month intervals throughout the first 2 years, and every 6 months thereafter. X-rays of the left hand and wrist are used to determine BA at baseline and once yearly thereafter. IGF-I and IGFBP-3 are measured at screening by a central laboratory, followed by every 3 months during the first year and every 6 months thereafter. IGF-I and IGFBP-3 serum levels are categorized as low (\-2 SD), normal, or high ([?2 SD), compared with the normal ranges for age and sex [12] . Fasting plasma glucose, insulin levels, and glycated hemoglobin (HbA 1c ) are measured at baseline, 6 months, 12 months, and annually thereafter.
OGTTs are conducted at the same time points.
All AEs are registered at each visit. Antibodies to GH were measured centrally using a validated radio-binding assay for non-neutralizing anti-GH antibodies.
Patient Populations and Statistical Analyses
The intention-to-treat population consisted of all subjects enrolled in the study who received at least one dose of study medication. The safety population comprised all patients who received at least one dose of study medication and had at least one post-baseline safety assessment.
The current analysis includes data from baseline up to the 2-year visit. Analyses were performed using SAS Version 9.1.3 or later (SAS Institute Inc., Cary, NC, USA). Descriptive statistics were used to evaluate homeostasis model assessment (HOMA), quantitative insulin sensitivity check index (QUICKI), IGF-I, IGFBP-3, and SDS for IGF-I and IGFBP-3. P values were calculated using paired t tests, with statistical significance defined as P\0.05.
RESULTS
Patients
Patients have been recruited and treated at 32 centers in 7 countries (Poland, Romania, Hungary, Czech Republic, Germany, Belgium, Georgia). In total, 278 children (148 males, 130 females) have been enrolled and received study medication; 249 have completed 2 years of treatment.
Twenty-nine children have therefore been withdrawn from the study (non-responders, n = 13; withdrawal of consent, n = 11; loss to follow-up, n = 3; protocol violation, n = 1; not taking medication, n = 1). 
Additional Safety Assessments
In total, 1093 AEs were reported in 211 (76.2%) children, most of which were mild-to-moderate in intensity (99.3%) and unrelated to study treatment (97.6%). The most commonly occurring AEs are shown in Table 3 . In total, 24 drug-related AEs occurred in 17 (6.1%) patients (hypothyroidism, n = 7; headache, n = 3; impaired fasting plasma glucose, n = 3; IGF-I/IGFBP-3 increased, n = 2;
thyroid-stimulating hormone increased, n = 1; puncture site hematoma, n = 1; scoliosis, n = 1;
upper respiratory tract infection, n = 1; bronchitis, n = 1; impaired glucose tolerance, n = 1; pharyngitis, n = 1; viral infection, n = 1; scarlet fever, n = 1). All (except one case of headache) were considered mild in severity, and none required study treatment to be permanently discontinued. Serious AEs were reported in 22 patients (7.9%), with only one (severe headache) suspected to be related to study treatment.
There have been no reports of malignancies or deaths during the first 2 years of treatment. Anti-rhGH antibody levels above the cut-off value were measured in 7 patients (2.7%) at Year 1 and in 3 patients (1.2%) at Year 2.
Positive test results were transient: only 2 (0.8%) patients had antibodies above the cut-off value in two separate visits.
Efficacy
Omnitrope treatment was effective, as shown by various height parameters. Mean HSDS is shown in Fig. 1 , and mean HVSDS in Fig. 2 of these, two patients had an SDS value below -2 and 25 patients had a value greater than ?2. IGF-I levels increased relatively more than IGFBP-3 levels, resulting in a rising IGF-I/ IGFBP-3 ratio (Figs. 3, 4) .
DISCUSSION
The primary objective of this study is to assess the effect of rhGH (Omnitrope) treatment on the development of diabetes in short children born SGA. Short children born SGA are thought to be at heightened risk of metabolic abnormalities, characterized by compensated insulin resistance without obvious abnormality of fasting or post-prandial glucose [13] . The insulin-antagonistic effects of GH treatment could potentially increase the risk of 2-year data are consistent with previous studies on the effects of rhGH treatment on glucose tolerance and insulin sensitivity in children born SGA [14, 15] . Our findings are also consistent with the previously proposed concept of a compensatory hyperinsulinemia that counters the GH-mediated increase in insulin resistance and maintains normal glucose regulation during treatment [16] . In addition, our data indicate no adverse alterations in body mass after 2 years of Omnitrope treatment; again, this is in line with other long-term studies of rhGH treatment in children born SGA [17] .
The safety profile of rhGH in SGA children is generally recognized as good [3] , and data from this 2-year analysis support this assertion. In the 1-year interim analysis, the incidence of treatment-related hypothyroidism and headache was 2.5% and 1.1%, respectively [10] ; no additional cases were reported after 2 years of rhGH treatment. The incidence of anti-rhGH antibodies after 2 years of treatment was also low, consistent with findings from long-term studies with Omnitrope in children with GH deficiency [18, 19] . . CI confidence interval, IGFBP-3 insulin-like growth factor-binding protein 3, IGF-I insulin-like growth factor I, SDS standard deviation score According to consensus guidelines, a change in HVSDS of more than ?0.5 within the first year of GH treatment is considered to be a positive growth response [4] . In the present study, HVSDS had to be at least ?1 after the first year of treatment for patients to be eligible to continue with therapy; therefore, all patients regarded as responders in the present study achieved a positive growth response as defined in the consensus guidelines. The improvement in growth parameters observed over 2 years' treatment with Omnitrope compares well with improvements reported in other studies of various rhGH products in short children born SGA [13, 14] .
Possible study limitations include the lack of a control group and the age of patients when rhGH treatment was initiated (most were aged C4 years). However, the clear treatment benefits observed in the majority of patients (increase in HV and net height gain) suggest that this is a population that is responsive to rhGH therapy. These data, in a large international cohort of children born SGA, are consistent with a positive risk-benefit ratio for Omnitrope. . CI confidence interval, IGFBP-3 insulin-like growth factor-binding protein 3, IGF-I insulin-like growth factor I, SDS standard deviation score
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